Authors
Latest:
Key Takeaways and Closing Thoughts on ADCsExperts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.
Latest:
Dr. Ulahannan on the PRODIGE 35 Trial in Pancreatic CancerSusanna Ulahannan, MD, assistant professor, Section of Hematology/Oncology, associate director, Oklahoma TSET Phase I Program, Stephenson Cancer Center, The University of Oklahoma, discusses the phase II PRODIGE 35/PANOPTIMOX trial in pancreatic cancer.
Latest:
Suzanne Fuqua Discusses the Y537 Hotspot in Breast CancerSuzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses the Y537 hotspot in breast cancer.
Latest:
Suzanne Beauchene on the Provenge Treatment ProcessSuzanne Beauchene from Seattle Cancer Care Alliance Discusses the Provenge Treatment Process from Start to Finish
Latest:
Dr. George on the Importance of Collaboration in the Treatment of Uterine SarcomasSuzanne George, MD, director of Clinical Research, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, and an associate professor of medicine, Harvard Medical School, discusses the importance of collaboration in the treatment of patients with uterine sarcoma.
Latest:
Dr. Topalian on the Immunosuppressive Tumor Microenvironment of Nasopharyngeal CancerSuzanne L. Topalian, MD, director, Melanoma Program, professor of Surgery and Oncology, Johns Hopkins Medicine, discusses the immunosuppressive microenvironment of nasopharyngeal cancer.
Latest:
Using Smartphones to Access Medical Reference InformationSmartphones are becoming the most transformational IT solution to ever impact healthcare.
Latest:
Dr. Rizvi on the Limitations of ABVD in Hodgkin LymphomaSyed Rizvi, MD, discusses the limitations of doxorubicin, bleomycin, vinblastine, and dacarbazine in Hodgkin lymphoma.
Latest:
Racial/Ethnic and Age Disparities in Chemotherapy Selection for Colorectal CancerStudies have evaluated racial/ethnic and age disparities in whether patients receive chemotherapy for nonmetastatic colo-rectal cancer
Latest:
Dr. Adams on the Utility of Combination CTLA-4 and PD-1 Blockade in Breast CancerSylvia Adams, MD, discusses the utility of combining anti–CTLA-4 and anti–PD-1 agents in breast cancer.
Latest:
Blocking the PD-1/PD-L1 Signaling Pathway in Malignant Glioma: Current and Future PerspectivesBlockade of the PD-1/PD-L1 pathway is a novel and attractive treatment approach to many cancers, including malignant glioma, because of its potential to restore anti-tumor immunity.
Latest:
Dr. Iqbal on Determining Whether to Start With Regorafenib or TAS-102 in mCRCSyma Iqbal, MD, discusses determining whether to start with regorafenib (Stivarga) or trifluridine/tipiracil (TAS-102; Lonsurf) in metastatic colorectal cancer (mCRC).
Latest:
The Long-Term Potential of Olaratumab in Soft Tissue SarcomaSymantha Melemed, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) in patients with soft tissue sarcoma
Latest:
Minimally Invasive Techniques Make Strides in Liver SurgeryDuring the past 15 years, minimally invasive general surgery has rapidly expanded to include laparoscopic and robotic techniques for cholecystectomy, colectomy, gastric weight loss, and other procedures
Latest:
Dr. Lazarus Discusses Companion DiagnosticsTadd Lazarus, MD, Chief Medical Officer, QIAGEN, provides an overview of companion diagnostics.
Latest:
Dr. Tahir Latif on Lower Male Survival Rates in Diffuse Large B-cell LymphomaTahir Latif, MD, associate professor of Medicine, interim chief, Division of Hematology Oncology, director, Infusion Services University of Cincinnati Cancer Institute, discusses differences in male survival rates versus female among patients with diffuse large B-cell lymphoma (DLBCL).
Latest:
Protecting privacy in the electronic era: HIPAA and HITECH mandatesIn 1890, Louise Brandeis and Samuel Warren published �¢ï¿½ï¿½The Right to Privacy�¢ï¿½ï¿½ in the Harvard Law Review, indicating private individuals were being injured by the invasions of modern-day technology
Latest:
Dr. Yoshino Discusses the Safety Profile of TAS-102Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses the safety profile of TAS-102 as seen in a phase III study of the agent versus placebo, with best supportive care, in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies.
Latest:
Dr. Zaks on Patient-Reported Symptom AssessmentsTal Zaks, MD, PhD, vice president and head of development at Sanofi Oncology, discusses patient-reported symptom assessment in the phase III JAKARTA trial of SAR302503 for myelofibrosis.
Latest:
Dr. Hilal on the Benefit of Maintenance Rituximab in Patients With MCLTalal Hilal, MB, BCh, assistant professor of Medicine at Mayo Clinic, discusses the benefit of maintenance rituximab (Rituxan) in the treatment of patients with mantle cell lymphoma (MCL).
Latest:
Addressing a Crisis of Authorship AbuseTalal Hilal, MD, on the ethical principles of medical authorship and a just distribution of credit.
Latest:
Dr. Golan on the Phase III POLO Trial in BRCA-Mutant Pancreatic CancerTalia Golan, MD, head of Sheba Pancreatic Cancer Center, discusses the results of the phase III POLO trial, which evaluated maintenance olaparib compared with placebo among patients with germline BRCA-mutated metastatic pancreatic cancer.
Latest:
Promoting HPV Vaccination for Girls and BoysOncology nurses can lead the way in efforts to protect the next generation from this type of cancer if they know the facts about HPV vaccination for both girls and boys
Latest:
Dr. Seiwert on Managing Side Effects for Head and Neck Cancer TreatmentTanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses managing toxicities associated with immunotherapy for patients with head and neck cancer.
Latest:
Dr. Seiwert on Final Thoughts on Immunotherapy in Head and Neck CancerTanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some final opinions on immunotherapy agents in the landscape of head and neck cancer.
Latest:
Dr. Seiwert on Pembrolizumab in Head and Neck CancerTanguy Seiwert, MD, assistant professor of medicine and associate leader of the head and neck cancer program, University of Chicago, discusses the efficacy of pembrolizumab in head and neck cancer.
Latest:
Dr. Seiwert on Immunotherapy in Head and Neck CancerTanguy Y. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the impact of immunotherapy agents as treatment of patients with head and neck cancer.
